Mesterolone

Mesterolone

Error creating thumbnail: File missing
Clinical data
ATC code	G03BB01 (WHO)
Identifiers
CAS Number	1424-00-6
PubChem CID	15020
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H32O2
Molar mass	304.467 g/mol

WikiDoc Resources for Mesterolone
Articles
Most recent articles on Mesterolone Most cited articles on Mesterolone Review articles on Mesterolone Articles on Mesterolone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mesterolone Images of Mesterolone Photos of Mesterolone Podcasts & MP3s on Mesterolone Videos on Mesterolone
Evidence Based Medicine
Cochrane Collaboration on Mesterolone Bandolier on Mesterolone TRIP on Mesterolone
Clinical Trials
Ongoing Trials on Mesterolone at Clinical Trials.gov Trial results on Mesterolone Clinical Trials on Mesterolone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mesterolone NICE Guidance on Mesterolone NHS PRODIGY Guidance FDA on Mesterolone CDC on Mesterolone
Books
Books on Mesterolone
News
Mesterolone in the news Be alerted to news on Mesterolone News trends on Mesterolone
Commentary
Blogs on Mesterolone
Definitions
Definitions of Mesterolone
Patient Resources / Community
Patient resources on Mesterolone Discussion groups on Mesterolone Patient Handouts on Mesterolone Directions to Hospitals Treating Mesterolone Risk calculators and risk factors for Mesterolone
Healthcare Provider Resources
Symptoms of Mesterolone Causes & Risk Factors for Mesterolone Diagnostic studies for Mesterolone Treatment of Mesterolone
Continuing Medical Education (CME)
CME Programs on Mesterolone
International
Mesterolone en Espanol Mesterolone en Francais
Business
Mesterolone in the Marketplace Patents on Mesterolone
Experimental / Informatics
List of terms related to Mesterolone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mesterolone is an orally applicable androgen, and DHT derivative. It is sold under the brand name Proviron, by Schering. In the late 70's and early 80's it was used with some success in controlled studies of men suffering from various forms of depression.

In one randomized, double-blind 4-week trial, 38 dysthymic men were administered 75mg daily. Itil & Colleagues reported an improvement of symptoms which included anxiety, lack of drive and desire. Next, they administered a high dose (450mg/day) or placebo in a 6-week randomized trial of 52 men with a mean age of 40 years, suffering from dysthymia, unipolar and bipolar depression. Both the mesterolone and placebo groups improved significantly and there were no statistically significant differences between the two groups. In this series of studies mesterolone lead to a significant decrease in LH and testosterone levels. This is probably as a result of the extremely high dose used. In another, 100mg mesterolone cipionate was administered twice monthly. With regards to plasma T levels, there was no difference between the treated vs untreated group, and baseline LH levels were minimally affected.

Mesterolone is a relatively weak androgen and rarely used for replacement therapies.

References

• Frances Morrison, Mary. (2000) Hormones, Gender and the Aging Brain: The Endocrine Basis of Geriatric Psychiatry, Page 134, Cambridge University Press. ISBN 0521653045.

• Itil et al. The effects of mesterolone, a male sex hormone in depressed patients. 1984.

Template:WikiDoc Sources